Dr. Alexander Wyatt is an associate professor in the Department of Urologic Sciences at the University of British Columbia. He is also cross-appointed at the Vancouver Prostate Centre and BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford.
Dr. Wyatt’s primary research goals are to identify associations between molecular alterations in metastatic genitourinary cancers and clinical outcomes, and to translate these findings into clinical biomarkers. He has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response. Learn more about his research here.
Dr. Wyatt is the chair of correlative sciences for genitourinary cancer trials run through the Canadian Cancer Trial Group (CCTG). He also serves as a member of the investigational new drug program executive committee. Dr. Wyatt directs the ctDNA screening strategy and the molecular tumor board for the first multi-center phase 2 umbrella trial in metastatic castration-resistant prostate cancer (NCT03385655, NCT02905318).
News and Awards
- Journal of the National Cancer Institute -
- Cancer discovery -
- European urology -
- Annals of oncology : official journal of the European Society for Medical Oncology -
- Nature communications -